Current Treatment of Cancer of the Kidney at Stage IV

2015 ◽  
pp. 116-122
Author(s):  
J. Cinqualbre ◽  
J. L. Wolf ◽  
P. Wolff
Keyword(s):  
Stage Iv ◽  
Current Treatment

scholarly journals Gastric Cancer Treatments and Survival Trends in the United States

2020 ◽  
Vol 28 (1) ◽  
pp. 138-151
Author(s):  
Kelly A. Stahl ◽  
Elizabeth J. Olecki ◽  
Matthew E. Dixon ◽  
June S. Peng ◽  
Madeline B. Torres ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Stage Iv ◽  
The United States ◽  
Current Treatment ◽  
Stage I ◽  
Stage Ii ◽  
Chi Square ◽  
Specific Guideline ◽  
Kaplan Meier

Gastric cancer is the third most common cause of cancer deaths worldwide. Despite evidence-based recommendation for treatment, the current treatment patterns for all stages of gastric cancer remain largely unexplored. This study investigates trends in the treatments and survival of gastric cancer. The National Cancer Database was used to identify gastric adenocarcinoma patients from 2004–2016. Chi-square tests were used to examine subgroup differences between disease stages: Stage I, II/III and IV. Multivariate analyses identified factors associated with the receipt of guideline concordant care. The Kaplan–Meier method was used to assess three-year overall survival. The final cohort included 108,150 patients: 23,584 Stage I, 40,216 Stage II/III, and 44,350 Stage IV. Stage specific guideline concordant care was received in only 73% of patients with Stage I disease and 51% of patients with Stage II/III disease. Patients who received guideline consistent care had significantly improved survival compared to those who did not. Overall, we found only moderate improvement in guideline adherence and three-year overall survival during the 13-year study time period. This study showed underutilization of stage specific guideline concordant care for stage I and II/III disease.

Current practices in 1st- (1L), 2nd- (2L), and 3rd-line (3L) treatment for metastatic colorectal cancer (mCRC).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14028-e14028 ◽  
Author(s):  
Stephen F Thompson ◽  
Sheikh Usman Iqbal ◽  
Sarah Naoshy ◽  
Daniel B Ng ◽  
Michael L Andria ◽  
...  
Keyword(s):  
Anticancer Agents ◽  
Unmet Need ◽  
Stage Iv ◽  
Current Treatment ◽  
Nccn Guidelines ◽  
Treatment Regimens ◽  
Lipid Metabolism Disorders ◽  
Advanced Therapies ◽  
Line Of Therapy ◽  
To Receive

e14028 Background: Up-to-date information concerning the optimal regimen assignment and sequencing of therapies is lacking for the treatment of mCRC patients. By tracking trends in treatment choice, this retrospective, observational study assesses current treatment patterns in mCRC patients by line of therapy. Methods: Using electronic medical record data from one of the largest US oncology databases (SDI), treatment regimens for 1L, 2L, and 3L were assessed for patients age ≥18 yrs diagnosed with mCRC from 1/1/04-7/31/11 who received anticancer agents. Results: 1,793 stage IV patients were identified in 1L, 1,050 in 2L, and 504 in 3L. Overall mean age was 60.4 yrs, and 54.6% were men. The most common comorbidities were hypertension (18.0%), lipid metabolism disorders (10.6%), and diabetes (8.6%). 47.8% had commercial insurance, 37.2% Medicare, 8.5% Medicaid, and 4.6% self pay. 1,026 patients received bevacizumab (B) in 1L, 583 in 2L, and 204 in 3L. Patients were more likely to receive FOLFOX (FX) + B in 1L and 2L. The top 3 regimens are shown in the table below. For patients who began treatment with B and continued B in a subsequent regimen, mean dose of B increased from 443.7 mg/kg (1L) to 567.0 mg/kg (2L) and 618.1 mg/kg (3L). Conclusions: FX is the regimen of choice in mCRC. In terms of biologics, B is more commonly used in 1L/2L than 3L. Given that approximately half the mCRC patients progressed to 2L/3L treatment, this likely reflects an unmet need for advanced therapies for the effective treatment of the disease. Furthermore, consistent dose escalation with continued B use across 2L/3L was seen despite that use of B in 3L mCRC is inconsistent with NCCN guidelines. Additional research on outcomes implications is needed, including mortality, patient toxicity, and costs. [Table: see text]

Current Treatment Approaches for Mantle-Cell Lymphoma

2005 ◽  
Vol 23 (26) ◽  
pp. 6409-6414 ◽  
Author(s):  
Thomas E. Witzig
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Single Agent ◽  
Stage Iv ◽  
Current Treatment ◽  
New Agents ◽  
Male Predominance ◽  
Response To Chemotherapy ◽  
Mantle Cell ◽  
Stage Iv Disease

Mantle-cell lymphoma (MCL) is now recognized as a distinct clinicopathologic subtype of B-cell non-Hodgkin's lymphoma. Patients with MCL are typically older adults with a male predominance and usually present with stage IV disease. The cells are characterized as CD20+ CD5+ CD23− with a t(11;14)(q13;q32) and cyclin D1 overexpression on immunohistochemistry. Response to chemotherapy usually results in a tumor response but unmaintained remissions are short and the median survival is 3 to 4 years. The treatment approach to newly diagnosed patients with MCL depends on the patient's eligibility for stem cell transplantation (SCT). Those who are eligible are usually treated with either rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by SCT or rituximab-HyperCVAD (cyclophosphamide, vincristine, doxorubicin, decadron, cytarabine, and methotrexate) followed by observation. The purine nucleoside analogues also have activity as single agents and with rituximab. Unfortunately none of these approaches can definitively cure patients with MCL, and new agents are needed. Recent studies in patients with relapsed MCL have shown substantial antitumor activity of single-agent bortezomib, single-agent temsirolimus, and the combination of thalidomide and rituximab. Studies integrating these novel agents earlier in the disease course or in combination with each other will hopefully produce more durable responses with less toxicity.

Patients' perception of palliative treatment objectives.

2016 ◽  
Vol 34 (26_suppl) ◽  
pp. 43-43
Author(s):  
Ahmed Gamal Elsayed ◽  
Maria R. B. Tria Tirona
Keyword(s):  
Stage Iv ◽  
Personal Communication ◽  
Health Care Team ◽  
Current Treatment ◽  
Educational Material ◽  
Treatment Goal ◽  
Comprehensive Cancer Center ◽  
Cancer Center ◽  
Palliative Intent ◽  
Stage Iv Disease

43 Background: Palliative chemotherapy and radiation are often used in patients with advanced stage of cancer. To weigh the risks and the benefits of this treatment, patients need to be adequately informed about all treatment aspects including the side effects and potential benefits. Unfortunately, many patients are not well informed about the goal of their treatment, and many are under the impression that this treatment can be curative. Methods: This is a prospective survey based study that enrolled 46 patients with stage IV disease of all solid malignancies, who are being treated with palliative intent at the Edwards Comprehensive Cancer Center. Patients were given a questionnaire designed to test their level of knowledge of their current treatment goals, and to evaluate the efforts of health care team to educate patients. Results: 35% of patients had lung cancer, 34% had GI cancer, 14% had breast cancer and 13% had GU cancers. 37% of patients were under the impression that they are receiving curative treatment, 28% were not sure about the goals of the treatment, while only 35% of patients understood that the treatment was not curative. 91% of patients received written educational material. 93% of patients chose personal communication with the physician as their preferred method of getting educated about their disease. Conclusions: Our data shows that most of the patients at our local cancer center who are actively receiving treatment with palliative intent are satisfied with amount of time spent with physician and have received written educational material. Despite these efforts, a majority of patients are still not clear on the treatment goal. Most patients chose personal discussion as the preferred method of education. Hence, physicians on staff were informed about the results and further emphasis on treatment goal during counseling is being undertaken. [Table: see text]

scholarly journals Current treatment strategies for patients with only peritoneal cytology positive stage IV gastric cancer

2021 ◽  
Vol 9 (32) ◽  
pp. 9711-9721
Author(s):  
Augustinas Bausys ◽  
Zilvinas Gricius ◽  
Laura Aniukstyte ◽  
Martynas Luksta ◽  
Klaudija Bickaite ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Treatment Strategies ◽  
Stage Iv ◽  
Current Treatment ◽  
Peritoneal Cytology ◽  
Stage Iv Gastric Cancer

Stage IV colorectal cancer: An NCDB analysis of the surgical treatment of peritoneal carcinomatosis versus liver metastases.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15067-e15067
Author(s):  
Samer A Naffouje ◽  
George I. Salti
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Peritoneal Carcinomatosis ◽  
Surgical Intervention ◽  
Stage Iv ◽  
Current Treatment ◽  
Surgical Approaches ◽  
Curative Intent ◽  
Stage Iv Colorectal Cancer ◽  
Significant Difference

e15067 Background: Traditionally, peritoneal carcinomatosis (PC) secondary to colorectal cancer (CRC) was perceived as a terminal disease, for which the only palliation was offered. With the emergence of new surgical approaches such as cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), surgical intervention in select patients with ‘curative’ intent was made possible. In this study, we compared the outcomes of the surgical intervention on stage IV CRC patients with isolated liver metastases (LM) to those with PC only. Methods: The National Cancer Database (NCDB) for CRC was analyzed excluding patients with PMP. Patients with isolated LM or with PC were identified, then divided into 2 treatment groups per the current treatment of each scenario: LM patients treated with surgery±chemotherapy (LM group), and PC patients treated with surgery+chemo±HIPEC (PC group). Results: 21,829 patients were identified; 18,932 fell in the LM group, and 2,897 in the PC group. Mean age in the LM and PC groups was 62.94±13.54 vs. 59.59±13.73. No significant difference was noted in the 30-day readmission rates (6.0% vs. 6.6%; p = 0.103). LM group had higher rates of 30- and 90-day mortality (4.3% vs. 0.3% and 8.6% vs. 1.8%, respectively; p < 0.0001), but a slightly shorter hospitalization (7.70±8.64 vs. 7.92±7.07; p = 0.024) Median overall survival was not different between the groups (27.3 vs. 25.36 months; p = 0.214). Conclusions: Surgery with systemic and IP chemotherapy can be a viable treatment option in stage IV CRC patients with PC with comparable short-term and survival outcomes to the widely accepted liver resection in patients with isolated LM.

Outcomes of Cervical Cancer and Positive Para-aortic Lymph Nodes in the Modern Era of Chemoradiation

2014 ◽  
Vol 24 (3) ◽  
pp. 564-569 ◽  
Author(s):  
LaToya J. Perry ◽  
Cara Mathews ◽  
Elizabeth Nugent ◽  
Regina Farrell ◽  
Kristen Zorn ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Lymph Nodes ◽  
Group Versus ◽  
Stage Iv ◽  
Progression Free Survival ◽  
Current Treatment ◽  
Outcome Data ◽  
Curative Intent ◽  
Treatment Regimens ◽  
Modern Era

ObjectivePatients with cervical cancer with positive para-aortic lymph nodes have a poor prognosis. Our primary aim was to describe outcomes among this subgroup in the era of modern chemoradiation.MethodsPatients with histologically confirmed cervical cancer metastatic to their para-aortic lymph nodes diagnosed between 1998 and 2011 and treated with curative intent were included in this analysis. Surgicopathologic, demographic, and outcome data were collected. Descriptive and survival statistics were generated to evaluate overall survival (OS) and progression-free survival (PFS) and to compare outcomes by treatment.Pvalues were generated using both Wilcoxon and log-rank methods and listed respectively.ResultsThe median PFS was 19 months. The median OS was 23.4 months. The median PFS for radiation only was 14 months and for chemoradiation was 20 months (P= 0.27 and 0.60, respectively). There was no difference in median OS for the radiation-only group versus chemoradiation. The median OS stratified by stage was 32 months (stage I), 21 months (stage II), 19.4 months (stage III), and 19.8 months (stage IV;P= 0.17 and 0.22).ConclusionsOur study shows a median OS of 23 months, which is less than what was documented in the literature. Despite the use of modern chemoradiation therapy, most of the cohort died within 3 years. The low OS presented in our study highlights the limitations of the current treatment regimens and the need for identification of for more effective therapy.

An Overview of Dementias

2012 ◽  
Vol 21 (3) ◽  
pp. 75-84
Author(s):  
Venkata Vijaya K. Dalai ◽  
Jason E. Childress ◽  
Paul E Schulz
Keyword(s):  
Clinical Presentation ◽  
Treatment Options ◽  
Current Treatment ◽  
Great Variability ◽  
Health Concern ◽  
Public Health Concern ◽  
Life Threatening ◽  
The Common ◽  
Neurodegenerative Dementias ◽  
Made In

Dementia is a major public health concern that afflicts an estimated 24.3 million people worldwide. Great strides are being made in order to better diagnose, prevent, and treat these disorders. Dementia is associated with multiple complications, some of which can be life-threatening, such as dysphagia. There is great variability between dementias in terms of when dysphagia and other swallowing disorders occur. In order to prepare the reader for the other articles in this publication discussing swallowing issues in depth, the authors of this article will provide a brief overview of the prevalence, risk factors, pathogenesis, clinical presentation, diagnosis, current treatment options, and implications for eating for the common forms of neurodegenerative dementias.

Melanoma Trial Shows Value of Surgery at Stage IV

2006 ◽  
Vol 37 (5) ◽  
pp. 1-8
Author(s):  
JANE SALODOF MACNEIL
Keyword(s):  
Stage Iv

Does Surgery Improve Survival in Stage IV Breast Cancer?

2011 ◽  
Vol 44 (10) ◽  
pp. 45
Author(s):  
DR. SEEMA KHAN ◽  
DR. BLAKE CADY
Keyword(s):  
Breast Cancer ◽  
Stage Iv ◽  
Stage Iv Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document